Serine protease inhibitor kazal (SPIK) compositions and methods
Anti-AS-SPIK antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to diagnose disorders characterized by the expression of AS-SPIK (e.g., liver cancer). Diagnostic methods and kits comprising the anti-AS-SPIK antibodies are also disclosed.
1. An isolated anti-Abnormal Secreted Serine Protease Inhibitor Kazal (anti-AS-SPIK) antibody, or an antigen-binding fragment thereof, that specifically binds to Abnormal Secreted Serine Protease Inhibitor Kazal (AS-SPIK), and does not bind to Normal Secreted Serine Protease Inhibitor Kazal (NS-SPIK), comprising:
(a) a CDRH1 sequence comprising SEQ ID NO: 15, a CDRH2 sequence comprising SEQ ID NO: 19, a CDRH3 sequence comprising SEQ ID NO: 23, a CDRL1 sequence comprising SEQ ID NO: 27, a CDRL2 sequence comprising SEQ ID NO: 31, and a CDRL3 sequence comprising SEQ ID NO: 35; or
(b) a CDRH1 sequence comprising SEQ ID NO: 16, a CDRH2 sequence comprising SEQ ID NO: 20, a CDRH3 sequence comprising SEQ ID NO: 24, a CDRL1 sequence comprising SEQ ID NO: 28, a CDRL2 sequence comprising SEQ ID NO: 32, and a CDRL3 sequence comprising SEQ ID NO: 36; or
(c) a CDRH1 sequence comprising SEQ ID NO: 17, a CDRH2 sequence comprising SEQ ID NO: 21, a CDRH3 sequence comprising SEQ ID NO: 25, a CDRL1 sequence comprising SEQ ID NO: 29, a CDRL2 sequence comprising SEQ ID NO: 33, and a CDRL3 sequence comprising SEQ ID NO: 37; or
(d) a CDRH1 sequence comprising SEQ ID NO: 18, a CDRH2 sequence comprising SEQ ID NO: 22, a CDRH3 sequence comprising SEQ ID NO: 26, a CDRL1 sequence comprising SEQ ID NO: 30, a CDRL2 sequence comprising SEQ ID NO: 34, and a CDRL3 sequence comprising SEQ ID NO: 38.
2. The antibody or antigen-binding fragment of claim 1 , wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 sequences are present within a framework sequence.
3. The antibody or antigen-binding fragment of claim 2 , wherein at least a portion of the framework sequence comprises a human consensus framework sequence.
4. The antibody or antigen-binding fragment of claim 3 , comprising:
(a) a heavy chain variable region sequence having at least 95% sequence identity to SEQ ID NO: 7 and a light chain variable region sequence having at least 95% sequence identity to SEQ ID NO: 11; or
(b) a heavy chain variable region sequence having at least 95% sequence identity to SEQ ID NO: 8 and a light chain variable region sequence having at least 95% sequence identity to SEQ ID NO: 12; or
(c) a heavy chain variable region sequence having at least 95% sequence identity to SEQ ID NO: 9 and a light chain variable region sequence having at least 95% sequence identity to SEQ ID NO: 13; or
(d) a heavy chain variable region sequence having at least 95% sequence identity to SEQ ID NO: 10 and a light chain variable region sequence having at least 95% sequence identity to SEQ ID NO: 14.
5. The antibody or antigen-binding fragment of claim 4 , comprising:
(a) a heavy chain variable region sequence comprising SEQ ID NO: 7 and a light chain variable region sequence comprising SEQ ID NO: 11; or
(b) a heavy chain variable region sequence comprising SEQ ID NO: 8 and a light chain variable region sequence comprising SEQ ID NO: 12; or
(c) a heavy chain variable region sequence comprising SEQ ID NO: 9 and a light chain variable region sequence comprising SEQ ID NO: 13; or
(d) a heavy chain variable region sequence comprising SEQ ID NO: 10 and a light chain variable region sequence comprising SEQ ID NO: 14.
6. A multispecific antibody comprising the anti-AS-SPIK antibody or antigen binding fragment thereof of claim 1 .
7. A bispecific antibody comprising the anti-AS-SPIK antibody or antigen binding fragment thereof of claim 1 .
8. The antibody or antigen-binding fragment of claim 1 , which is monoclonal.
9. A diagnostic method for determining whether a subject has hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), or cirrhosis of the liver, the method comprising:
(a) contacting a biological test sample from the subject with an anti-Abnormal Secreted Serine Protease Inhibitor Kazal (anti-AS-SPIK) antibody, or an antigen-binding fragment thereof, that specifically binds to AS-SPIK, and does not bind to Normal Secreted Serine Protease Inhibitor Kazal (NS-SPIK), to generate an AS-SPIK-antibody complex, wherein the anti-AS-SPIK antibody or antigen-binding fragment thereof comprises:
(i) a CDRH1 sequence comprising SEQ ID NO: 15, a CDRH2 sequence comprising SEQ ID NO: 19, a CDRH3 sequence comprising SEQ ID NO: 23, a CDRL1 sequence comprising SEQ ID NO: 27, a CDRL2 sequence comprising SEQ ID NO: 31, and a CDRL3 sequence comprising SEQ ID NO: 35; or
(ii) a CDRH1 sequence comprising SEQ ID NO: 16, a CDRH2 sequence comprising SEQ ID NO: 20, a CDRH3 sequence comprising SEQ ID NO: 24, a CDRL1 sequence comprising SEQ ID NO: 28, a CDRL2 sequence comprising SEQ ID NO: 32, and a CDRL3 sequence comprising SEQ ID NO: 36; or
(iii) a CDRH1 sequence comprising SEQ ID NO: 17, a CDRH2 sequence comprising SEQ ID NO: 21, a CDRH3 sequence comprising SEQ ID NO: 25, a CDRL1 sequence comprising SEQ ID NO: 29, a CDRL2 sequence comprising SEQ ID NO: 33, and a CDRL3 sequence comprising SEQ ID NO: 37; or
(iv) a CDRH1 sequence comprising SEQ ID NO: 18, a CDRH2 sequence comprising SEQ ID NO: 22, a CDRH3 sequence comprising SEQ ID NO: 26, a CDRL1 sequence comprising SEQ ID NO: 30, a CDRL2 sequence comprising SEQ ID NO: 34, and a CDRL3 sequence comprising SEQ ID NO: 38;
(b) detecting a concentration of the AS-SPIK-antibody complex in the biological test sample; and
(c) comparing the concentration of the AS-SPIK-antibody complex to a reference value to determine whether the subject has hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), or cirrhosis of the liver.
10. The diagnostic method of claim 9 , wherein the anti-AS-SPIK antibody or antigen-binding fragment thereof comprises a detectable label.
11. A kit comprising an anti-Abnormal Secreted Serine Protease Inhibitor Kazal (anti-AS-SPIK) antibody, or an antigen-binding fragment thereof, that specifically binds to Abnormal Secreted Serine Protease Inhibitor Kazal (AS-SPIK), and does not bind to Normal Secreted Serine Protease Inhibitor Kazal (NS-SPIK), comprising:
(a) a CDRH1 sequence comprising SEQ ID NO: 15, a CDRH2 sequence comprising SEQ ID NO: 19, a CDRH3 sequence comprising SEQ ID NO: 23, a CDRL1 sequence comprising SEQ ID NO: 27, a CDRL2 sequence comprising SEQ ID NO: 31, and a CDRL3 sequence comprising SEQ ID NO: 35; or
(b) a CDRH1 sequence comprising SEQ ID NO: 16, a CDRH2 sequence comprising SEQ ID NO: 20, a CDRH3 sequence comprising SEQ ID NO: 24, a CDRL1 sequence comprising SEQ ID NO: 28, a CDRL2 sequence comprising SEQ ID NO: 32, and a CDRL3 sequence comprising SEQ ID NO: 36; or
(c) a CDRH1 sequence comprising SEQ ID NO: 17, a CDRH2 sequence comprising SEQ ID NO: 21, a CDRH3 sequence comprising SEQ ID NO: 25, a CDRL1 sequence comprising SEQ ID NO: 29, a CDRL2 sequence comprising SEQ ID NO: 33, and a CDRL3 sequence comprising SEQ ID NO: 37; or
(d) a CDRH1 sequence comprising SEQ ID NO: 18, a CDRH2 sequence comprising SEQ ID NO: 22, a CDRH3 sequence comprising SEQ ID NO: 26, a CDRL1 sequence comprising SEQ ID NO: 30, a CDRL2 sequence comprising SEQ ID NO: 34, and a CDRL3 sequence comprising SEQ ID NO: 38.
12. The kit of claim 11 , further comprising an antibody or antigen-binding fragment thereof that specifically binds to SPIK.
13. The kit of claim 11 , further comprising an antibody or antigen-binding fragment thereof that specifically binds to both AS-SPIK and NS-SPIK.
14. The kit of claim 11 , wherein the antibody or antigen-binding fragment thereof that specifically binds to AS-SPIK, and does not bind to NS-SPIK, is pre-bound to an assay device.